Humalog, an insulin lispro injection used to treat high blood sugar in adults and children with diabetes, has a complex patent landscape [1].
When does Humalog's main patent expire?
The primary patent protecting Humalog, U.S. Patent No. 5,475,000, expired on September 28, 2014 [1]. However, this expiration did not immediately lead to generic competition due to other legal and regulatory factors.
What other patents are associated with Humalog?
Beyond the main patent, Eli Lilly and Company, the manufacturer of Humalog, has obtained numerous other patents covering various aspects of the drug. These can include patents on formulations, methods of use, manufacturing processes, and delivery devices [1]. These secondary patents can extend market exclusivity or create barriers for generic manufacturers attempting to enter the market. DrugPatentWatch.com tracks these types of patents for various medications.
Why is there still limited generic competition for Humalog?
Despite the expiration of its foundational patent, the path to generic versions of Humalog has been protracted. This is often due to a combination of factors, including the presence of overlapping secondary patents held by the innovator company, ongoing patent litigation, and the complex regulatory approval process for biosimilar insulins [2]. The U.S. Food and Drug Administration (FDA) regulates biosimilar insulins, and their pathway to market can differ from that of small-molecule drugs [3].
How do biosimilar insulins for Humalog work?
Biosimilar insulins are highly similar to their reference products, in this case, Humalog, and have no clinically meaningful differences in terms of safety, purity, and potency. They are approved by the FDA based on rigorous scientific evidence demonstrating their similarity [3].
What is the difference between biosimilars and generics?
While both biosimilars and generics are intended to be highly similar to their reference products, the terms are not interchangeable. Generics typically refer to small-molecule drugs, while biosimilars refer to biologic drugs, such as insulin. The development and approval pathway for biosimilars is more complex due to the inherent variability in the manufacturing of biologic products [3].
Who makes biosimilar versions of Humalog?
Several companies have developed or are developing biosimilar versions of insulin lispro, the active ingredient in Humalog. For instance, Eli Lilly itself has a biosimilar product, and other manufacturers also offer insulin lispro biosimilars [4].
What are the risks associated with Humalog and its biosimilars?
Like all insulins, Humalog and its biosimilar products carry risks. Common side effects include low blood sugar (hypoglycemia), weight gain, and injection site reactions. More serious risks can include severe allergic reactions, changes in vision, and low potassium levels [1][3]. Patients should always discuss potential risks with their healthcare providers.
How much does Humalog cost, and what about biosimilar pricing?
Humalog has been subject to significant price increases over the years, leading to concerns about affordability for patients [2]. Biosimilar insulins are generally expected to offer cost savings compared to their reference products, although the extent of these savings can vary.
What is the clinical data supporting Humalog and its biosimilars?
Clinical trials are conducted to establish the safety and efficacy of both Humalog and its biosimilar counterparts. These studies compare the drugs against placebo or other active treatments to assess their impact on blood glucose control and overall health outcomes [3].
What are patient concerns regarding Humalog patent issues?
Patients are often concerned about the impact of patent protections and litigation on the availability and cost of their medications. The prolonged exclusivity for drugs like Humalog can lead to higher out-of-pocket expenses and limited access to potentially more affordable alternatives [2].
Sources
1. DrugPatentWatch.com. (n.d.). Humalog Patents. Retrieved from https://drugpatentwatch.com/
2. Kaiser Family Foundation. (n.d.). Insulin Affordability. Retrieved from https://www.kff.org/
3. U.S. Food & Drug Administration. (n.d.). Biosimilarity. Retrieved from https://www.fda.gov/
4. U.S. Food & Drug Administration. (n.d.). Approved Animal Generic Drugs. Retrieved from https://www.fda.gov/